Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Open accessPublished version of a preprint
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the safety, pharmacokinetics, and recommended phase II dose of an antibody–drug conjugate (ADC) targeting ectonucleotide phosphodiesterases-pyrophosphatase 3 (ENPP3) conjugated to monomethyl auristatin F (MMAF) in subjects with advanced metastatic renal cell carcinoma (mRCC). Patients and Methods: Two phase I studies were conducted sequentially with 2 ADCs considered equivalent, hybridoma-derived AGS-16M8F and Chinese hamster ovary–derived AGS-16C3F. AGS-16M8F was administered intravenously every 3 weeks at 5 dose levels ranging from 0.6 to 4.8 mg/kg until unacceptable toxicity or progression. The study was terminated before reaching the MTD. A second study with AGS-16C3F started with the AGS-16M8F bridging dose of 4.8 mg/kg given every 3 weeks. Results: The AGS-16M8F study (n = 26) closed before reaching the MTD. The median duration of treatment was 12 weeks (1.7–83 weeks). One subject had durable partial response (PR; 83 weeks) and 1 subject had prolonged stable disease (48 weeks). In the AGS-16C3F study (n = 34), the protocol-defined MTD was 3.6 mg/kg, but this was not tolerated in multiple doses. Reversible keratopathy was dose limiting and required multiple dose deescalations. The 1.8 mg/kg dose was determined to be safe and was associated with clinically relevant signs of antitumor response. Three of 13 subjects at 1.8 mg/kg had durable PRs (range, 100–143 weeks). Eight subjects at 2.7 mg/kg and 1.8 mg/kg had disease control >37 weeks (37.5–141 weeks). Conclusions: AGS-16C3F was tolerated and had durable antitumor activity at 1.8 mg/kg every 3 weeks. Clin Cancer Res; 24(18); 4399–406. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Research works printed but not linked: 18
- Buti, 2013, Chemotherapy in metastatic renal cell carcinoma today? A systematic review, Anticancer Drugs, 24, 535, 10.1097/CAD.0b013e3283609ec1 · DOI
- Diamond, 2015, Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy, Crit Rev Oncol Hematol, 96, 518, 10.1016/j.critrevonc.2015.08.007 · DOI
- Hartmann, 1999, Chemotherapy for renal cell carcinoma, Anticancer Res, 19, 1541
- de Goeij, 2016, New developments for antibody-drug conjugate-based therapeutic approaches, Curr Opin Immunol, 40, 14, 10.1016/j.coi.2016.02.008 · DOI · Paper page
- Doronina, 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity, Bioconjug Chem, 17, 114, 10.1021/bc0502917 · DOI · Paper page
- Donate, 2016, AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma, Clin Cancer Res, 22, 1989, 10.1158/1078-0432.CCR-15-1542 · DOI
- Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 · DOI · Paper page
- Zhao, 2018, Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates, Cancer Res, 78, 2115, 10.1158/0008-5472.CAN-17-3202 · DOI · Paper page
- Zhao, 2017, Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia, Mol Cancer Ther, 16, 1877, 10.1158/1535-7163.MCT-16-0710 · DOI · Paper page
- McCarty, 1986, Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors, Cancer Res, 46, 4244s
- Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 · DOI · Paper page
- Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 · DOI · Paper page
- Von Hoff, 2010, Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, 28, 4877, 10.1200/JCO.2009.26.5983 · DOI · Paper page
- Al-Rohil, 2016, Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding, J Cutan Pathol, 43, 1161, 10.1111/cup.12797 · DOI
- Loganzo, 2016, Mechanisms of resistance to antibody-drug conjugates, Mol Cancer Ther, 15, 2825, 10.1158/1535-7163.MCT-16-0408 · DOI · Paper page
- Tannir, 2014, Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma, Invest New Drugs, 32, 1246, 10.1007/s10637-014-0151-0 · DOI
- Eaton, 2015, Ocular adverse events associated with antibody-drug conjugates in human clinical trials, J Ocul Pharmacol Ther, 31, 589, 10.1089/jop.2015.0064 · DOI · Paper page
- Younes, 2012, Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma, J Clin Oncol, 30, 2776, 10.1200/JCO.2011.39.4403 · DOI · Paper page
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Self-citationOcular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
Metadata
- Authors
- Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F., & Kollmannsberger, C. K.
- Venue
- Clinical Cancer Research
- Published
- 2018-09-14
- Volume
- 24
- Issue
- 18
- Pages
- 4399-4406
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2807016784
- Cited by
- 67
- References
- 1
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0481
- The paper
- Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F., & Kollmannsberger, C. K. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.